



Professor Carl Kirkpatrick is the Director of the Centre for Medicines Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. Since receiving his Doctor of Philosophy (Medicine) from the University of Otago (NZ) in 2002, Carl has worked at the University of Queensland and more recently Monash University. Carl has extensive knowledge in the area of PK/PD modeling and the factors that alter these processes, pre-clinical and clinical drug development, and clinical applications to optimization of therapy. He has worked on projects and produced publications across a number of therapeutic areas including diabetes, cardiovascular disease, cancer, aged/frailty, and infectious diseases (bacteria, viruses, and fungi).

Carl has been a member of PAGANZ since attending its inaugural meeting in Auckland in 1999. Carl has been part of the organising committee and leadership group of PAGANZ (now PAGANZ Inc) for a large part of the last 17 years. Most recently he held the position of Secretary for PAGANZ Inc. He has hosted/co-hosted 4 PAWs/PAGANZ events in New Zealand and Australia (Christchurch, Brisbane, and Melbourne (2012 & 2015)). More recently he was the Chair of the Scientific Committee and part of the PAGANZ Inc team hosting the 2016 WCOP meeting in Brisbane.

Carl has been a member of the former Pharmaceutical Sub-Committee of the TGA from 2008 until its closure in 2016, and continues this role as an expert advisor to the TGA at present in the area of Pharmacometrics. He is an Executive Editor for the British Journal of Clinical Pharmacology and Editor for Journal of Antimicrobial Chemotherapy. He is currently the President Elect for the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists.

Carl has extensive experience in contributing to PAGANZ and the wider pharmacometrics community. He wishes to be re-elected as a Committee Member to provide his ongoing support and guidance to PAGANZ Inc. This is to ensure the profile of pharmacometrics in drug development and regulatory affairs is maintained in Australia and New Zealand. Furthermore to ensure we have appropriate training to produce high quality pharmacometricians for academia and industry in the Asia-Pacific region via PAGANZ and university training programs.